Notfälle in der medikamentösen Tumortherapie – Operative Indikationen unter Systemtherapie

Constantin Rieger; David Pfister; Axel Heidenreich

doi:10.1055/a-2129-7104

Aktuelle Urologie, Table of Contents

Aktuelle Urol 2024; 55(01): 60-64
DOI: 10.1055/a-2129-7104

Übersicht

Notfälle in der medikamentösen Tumortherapie – Operative Indikationen unter Systemtherapie

Emergencies in cancer therapy: surgical indications under systemic therapy

Constantin Rieger

¹Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany (Ringgold ID: RIN27182)

,

David Pfister

¹Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany (Ringgold ID: RIN27182)

,

Axel Heidenreich

¹Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany (Ringgold ID: RIN27182)

› Author Affiliations

Abstract

Zusammenfassung

Operative Indikationen aufgrund von Nebenwirkungen unter Systemtherapie bei einem metastasierten Tumor des Urogenitaltrakts sind selten. Nichtsdestotrotz gibt es eine Reihe von Notfällen, welche eine rasche Intervention erfordern und von jedem Uroonkologen erkannt werden sollten. Die folgende Übersichtarbeit wird wichtige Nebenwirkungen mit der Notwendigkeit einer operativen Therapie herausarbeiten, indem die wesentlichen Symptome sowie das initiale Management dargestellt werden.

Abstract

Emergency surgery due to side-effects of cancer therapy in patients with metastatic disease of the genitourinary tract is rare. Nevertheless, there are a number of emergencies that require rapid intervention and should be recognized by every uro-oncologist. The following review will work out important side-effects requiring surgical treatment, highlighting the main symptoms and the initial management.

Schlüsselwörter

Operative Indikation - Chemotherapie - Nebenwirkungen

Keywords

chemotherapy - surgical intervention - side-effects

Full Text

References

Literatur
1 Mettias B, Robertson S, Buchanan MA. Retropharyngeal abscess after chemotherapy. BMJ Case Rep 2018; 2018
2 Opitz D, Camerer C, Camerer D-M. et al. Incidence and management of severe odontogenic infections – a retrospective analysis from 2004 to 2011. J Craniomaxillofac Surg 2015; 43: 285-289
3 Cunnington A, Brick T, Cooper M. et al. Severe invasive Panton-Valentine Leucocidin positive Staphylococcus aureus infections in children in London, UK. J Infect 2009; 59: 28-36
4 Klug TE, Greve T, Hentze M. Complications of peritonsillar abscess. Ann Clin Microbiol Antimicrob 2020; 19: 32
5 Brunello A, Saia G, Bedogni A. et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44: 173-175
6 Smith MR, Saad F, Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
7 Walter C, Al-Nawas B, Grötz KA. et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008; 54: 1066-1072
8 Khan AA, Morrison A, Hanley DA. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30: 3-23
9 Haring A. S3-Leitlinie Prostatakarzinom.
10 Badheeb A, Alkhanbashi O, Rakrouki S. et al. Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report. Pan Afr Med J 2022; 42: 98
11 Sato S, Senmaru N, Ishido K. et al. Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report. Surg Case Rep 2019; 5: 166
12 Marin-Acevedo JA, Harris DM, Burton MC. Immunotherapy-Induced Colitis: An Emerging Problem for the Hospitalist. J Hosp Med 2018; 13: 413-418
13 Beck TN, Kudinov AE, Dulaimi E. et al. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019; 19: 379
14 Badgwell BD, Camp ER, Feig B. et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008; 19: 577-582
15 Schultz NM, Penson DF, Wilson S. et al. Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. Drug Saf 2020; 43: 23-33
16 Yang P, Zheng Y, Zhang L. et al. Incidence and characteristics of death from peptic ulcer among cancer patients in the United States. Sci Rep 2021; 11: 23579
17 Paffenholz P, Grein K, Heidegger I. et al. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol 2019; 37: 1907-1916
18 Cameron AC, McMahon K, Hall M. et al. Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer. JACC CardioOncol 2020; 2: 443-455
19 Sato C, Okuda K, Tamiya H. et al. Acute Arterial Thrombosis during Postoperative Adjuvant Cisplatin-based Chemotherapy for Completely Resected Lung Adenocarcinoma. Intern Med 2018; 57: 557-561
20 Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002; 22: 1200-1204
21 Rini BI, Moslehi JJ, Bonaca M. et al. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol 2022; 40: 1929-1938
22 Solinas C, Saba L, Sganzerla P. et al. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thromb Res 2020; 196: 444-453
23 Deutsche Gesellschaft für Kardiologie. Diagnostik und Therapie der peripheren arteriellen Erkrankungen. https://leitlinien.dgk.org/files/2012_Pocket-Leitlinien_Diagnostik_arteriellen_Erkrankungen.pdf
24 Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med 2012; 366: 2198-2206
25 Barone M, Grani G, Ramundo V. et al. Fournier's gangrene during lenvatinib treatment: A case report. Mol Clin Oncol 2020; 12: 588-591
26 Bruketa T, Majerovic M, Augustin G. Rectal cancer and Fournierʼs gangrene - current knowledge and therapeutic options. World J Gastroenterol 2015; 21: 9002-9020
27 Saleem N, Devan WJ, Pitts DR. et al. Unusual cause of Fournierʼs gangrene: colorectal-genitourinary tract fistulae status post brachytherapy. BMJ Case Rep 2020; 13
28 Bowen D, Juliebø-Jones P, Somani BK. Global outcomes and lessons learned in the management of Fournier's gangrene from high-volume centres: findings from a literature review over the last two decades. World J Urol 2022; 40: 2399-2410
29 Radcliffe RS, Khan MA. Mortality associated with Fournier's gangrene remains unchanged over 25 years. BJU Int 2020; 125: 610-616